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ABSTRACT
Objectives To estimate the incidence and prevalence
of systemic lupus erythematosus (SLE) in the UK over the
period 1999–2012.
Methods A retrospective cohort study using the
Clinical Practice Research Datalink (CPRD). The incidence
was calculated per 100 000 person-years and the
prevalence was calculated per 100 000 people for the
period 1999–2012 and stratiﬁed by year, age group,
gender, region and ethnicity. Three deﬁnitions of SLE
were explored: (1) systemic lupus, (2) a fully
comprehensive deﬁnition of lupus including cutaneous
only lupus and (3) requiring supporting evidence of SLE
in the medical record.
Results Using our primary deﬁnition of SLE, the
incidence during the study period was 4.91/100 000
person-years (95% CI 4.73 to 5.09), with an annual
1.8% decline (p<0.001). In contrast, the prevalence
increased from 64.99/100 000 in 1999 (95% CI 62.04
to 67.93) (0.065%) to 97.04/100 000 in 2012 (95% CI
94.18 to 99.90) (0.097%). SLE was six times more
common in women. The peak age of incidence was 50–
59 years. There was regional variation in both incidence
and prevalence. People of Black Caribbean ethnicity had
the highest incidence and prevalence. Alternative
deﬁnitions of SLE increased (deﬁnition 2) or decreased
(deﬁnition 3) estimates of incidence and prevalence, but
similar trends were found.
Conclusions The incidence of SLE has been declining
but the prevalence has been increasing in the UK in
recent years. Age, gender, region and ethnicity are risk
factors for SLE. This is the ﬁrst study to report ethnic
differences on the incidence and prevalence of SLE using
the CPRD.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a rare,
chronic autoimmune disease which can vary from
mild to potentially life-threatening. The majority of
previous studies that estimated the incidence and
prevalence of SLE in the UK were single-centre
hospital-based studies.1–5 These estimated the inci-
dence to be 3.8–4.0/100 000 person-years and the
prevalence 6.5–27.7/100 000 people. Most only
included patients who fulﬁlled four of the 1982
American College of Rheumatology (ACR) classiﬁ-
cation criteria,6 thereby excluding mild cases or
those who did not fulﬁl four criteria despite severe
disease, for example, lupus nephritis. More recently,
the Clinical Practice Research Datalink (CPRD), for-
merly known as the General Practice Research
Database, has been used for this purpose. Using the
CPRD, the incidence for SLE during the 1990s was
estimated to be between 3.0 (95% CI 2.7 to 3.3)
and 4.7 (95% CI 4.5 to 4.9)/100 000 person-years
and the prevalence between 25.0 (95% CI 23.4 to
26.7) and 40.7 (95% CI 37.6 to 43.8)/100 000
persons.7–9 The incidence estimates differed due to
variation in deﬁning the study population and inci-
dent cases.10 Both excluded certain subtypes of
cutaneous lupus and were more likely to exclude
mild cases. The prevalence estimates increased with
time during the 1990s. This was suggested to be due
to recording a relapsing-remitting disease within a
longitudinal database, rather than an actual increase
in prevalence. However, one of the incidence
studies found a small but non-signiﬁcant increase in
the incidence of SLE in females over time and
studies in other European countries have found an
increased temporal trend.11–13
The aim of this study was to examine the inci-
dence and prevalence for SLE in the UK for the
most recent decade, including temporal trends,
variation with age, gender, region and ethnicity. To
better understand the nature of SLE, three different
deﬁnitions were examined: (1) systemic lupus, (2) a
fully comprehensive deﬁnition of lupus including
cutaneous only lupus and (3) any lupus case with
supporting evidence of SLE in the medical record.
METHOD
Study design and study population
A retrospective cohort study was conducted using
the CPRD, a longitudinal database of UK general
practice records incepted in 1987 and deemed to be
representative of the UK population.14 As of
January 2013, there were 660 practices contributing
anonymised records for approximately 12 million
people in all four countries of the UK. Practices
record patient demographics, consultations, hospita-
lisations, specialist referrals, prescriptions, test
results, immunisations and diagnoses using Vision
Practice Management Software. Clinical informa-
tion is entered using Read codes, a standard clinical
terminology system used in general practice in the
UK. Prescriptions are recorded using Multilex (or
British National Formulary (BNF)) codes.
Researchers access data through the CPRD website
or annual ﬂat ﬁles. The quality of the data is regu-
lated by the Medicines and Healthcare Products
Regulatory Authority (MHRA).
Participants were males and females contributing
data during the period 1 January 1999 to 31
December 2012. Participants were eligible from the
date their practice was deemed to be contributing
Open Access
Scan to access more
free content
Clinical and epidemiological research
136 Rees F, et al. Ann Rheum Dis 2016;75:136–141. doi:10.1136/annrheumdis-2014-206334
group.bmj.com on January 9, 2016 - Published by http://ard.bmj.com/Downloaded from 
‘up-to-standard’ (UTS) data and their individual record was of
‘acceptable’ research quality as veriﬁed by the CPRD. When cal-
culating incidence at least 12 months registration prior to study
entry was required. A minimum period of 1 year following
registration has been suggested to minimise the risk of prevalent
cases being coded as incident cases for chronic diseases15 and
was used in a previous SLE study.8 A minimum period of
3 years postregistration was analysed for comparison.
For consenting English practices, ethnic group data were avail-
able through linkage to Hospital Episode Statistics (HES). HES
records patient demographics, primary diagnosis, procedures,
intensive care stays and maternity data for hospital admissions
since 1997 using International Classiﬁcation of Diseases
(ICD)-10 codes. Linked data were only used to obtain ethnic
group as this was not available on the January 2013 release of the
CPRD dataset.
Independent Scientiﬁc Advisory Committee for MHRA
Database Research approval was obtained for this study on 4
June 2013 (Protocol 13_092).
Case deﬁnition
Read codes for SLE were selected from the CPRD medical dic-
tionary browser using the search terms ‘lupus’ and ’SLE’ (see
online supplementary table S1). Three deﬁnitions were used.
The ﬁrst deﬁnition ‘systemic lupus’ included all codes that repre-
sented SLE or a subtype of SLE excluding cutaneous only lupus.
Codes relating to a diagnostic test, a scoring system, tubercu-
losis, lupus pernio, drug-induced lupus or neonatal lupus were
excluded. Selected codes were veriﬁed by 6 co-investigators (3
rheumatologists (FR, MD, PL), 1 epidemiologist (WZ), 1 statis-
tician and CPRD expert (MG) and 1 general practitioner (GP)
(GD)). The second deﬁnition was fully comprehensive including
cases with cutaneous only subtypes. The third deﬁnition
required a record of either a positive immunological blood test
result (ANA, anti-dsDNA, ENA or anti-Ro), a prescription for a
drug used in SLE (hydroxychloroquine, azathioprine, metho-
trexate, mycophenolate mofetil, ciclosporin, cyclophosphamide,
rituximab, prednisolone) or a referral to a rheumatologist from
cases identiﬁed in deﬁnition 2.
The date of ﬁrst code was taken as the date of diagnosis.
Individuals with a code for SLE but without a diagnosis date
were excluded (n=49).
External validation of SLE diagnosis was not conducted
because: (1) there was no additional funding or time available
for this; (2) GPs would be unlikely to give a patient a Read code
for SLE unless it had been conﬁrmed by a hospital specialist
(personal communication, GD); and (3) validation of other
autoimmune diseases on the CPRD has shown positive predict-
ive values of >90%.16 17
Outcome measures and analysis
Incidence was calculated by dividing the number of new cases of
SLE by the number of person-years from eligible participants
during the study period. For each year of follow-up, the entry
date was the latest of 1 January, UTS date or the date of registra-
tion plus 365 days. The exit date was the earliest date of inci-
dent SLE diagnosis, death, transfer-out of a participating CPRD
practice, date of last data collection from a practice or 31
December of the speciﬁed year.
Prevalent cases were all live cases of SLE on the database
meeting the eligibility criteria on the 1 July of each year. Point
prevalence was calculated by dividing the number of prevalent
cases by the number of people on the CPRD who had UTS and
‘acceptable’ data on the 1 July of each year.
Incidence and prevalence were presented by age, gender and
region and expressed per 100 000 person-years or people with
95% CIs. Ten year age-bands were selected for age stratiﬁcation.
Direct standardisation by age and gender used the 2012 popula-
tion as a reference. The trend with time and region was analysed
using Poisson regression adjusting for age and gender with an
interaction term. A subsequent analysis of prevalence over time
also adjusted for length of data contribution.
Using only individuals from HES-linked practices, the SLE inci-
dence and prevalence in different ethnic groups were estimated.
Data management and analysis were performed using
StataMP4 software V.13 (Statacorp, Texas, USA). The signiﬁcance
level was 0.05.
RESULTS
Incidence
A total of 8 681 127 people contributed 55 839 080 person-years
of follow-up, of whom 2740 had a new diagnosis of SLE (inci-
dence 4.91 per 100 000 person-years; 95% CI 4.73 to 5.09).
Temporal trend
Table 1 shows the trend in incidence by year. There was an
annual 1.8% decline (95% CI 0.8 to 2.7, p for trend <0.001)
with a peak incidence in the year 2000 (5.93/100 000 person-
years (95% CI 5.14 to 6.83)) and a minimum in the year 2010
(4.00/100 000 person-years (95% CI 3.45 to 4.64)). For com-
parison, when using a minimum of 3 years of registration, the
annual incidence declined by 1.9% (95% CI 0.9 to 2.9, p for
trend<0.001) with a peak of 5.34/100 000 person-years (95%
CI 4.60 to 6.20) in 2000 and a minimum of 3.51/100 000
person-years (95% CI 3.00 to 4.12) in 2010.
Age and gender
The incidence in females was 5.8 times that of males (8.34/
100 000 person-years (95% CI 8.01 to 8.69) vs 1.44/100 000
person-years (95% CI 1.30 to 1.58), p<0.001). The mean age
at diagnosis was 48.9 years (SD 16.9). Women were signiﬁcantly
younger than men at diagnosis (48.3 years (SD 16.8) vs
52.1 years (SD 17.2), p<0.001). The peak age of incidence for
women (40–49 years) was earlier than that for men (60–
69 years) (ﬁgure 1A). The incidence was greater in females com-
pared with males for all ages.
Region
There was geographic variation in incidence, with the lowest in
the West Midlands (3.87/100 000 person-years (95% CI 3.31 to
4.43)) and the highest in the East of England (6.03/100 000
person-years (95% CI 5.36 to 6.69)) (ﬁgure 2A). There was no
obvious trend with latitude, but the overall effect of region was
statistically signiﬁcant (p<0.001).
Ethnicity
Of the 8 681 127 participants, 5 408 624 were attending
HES-linked practices, including 1643 incident cases (60%).
Table 2 illustrates the variation in SLE incidence by ethnicity.
People of Black Caribbean ethnicity had the highest incidence
(31.46/100 000 person-years (95% CI 22.48 to 44.03)). In com-
parison, the incidence in White people was 6.73/100 000
person-years (95% CI 6.35 to 7.14). The effect of ethnic group
on incidence was statistically signiﬁcant (p<0.001).
Alternative deﬁnitions
Using the fully comprehensive deﬁnition, the incidence was
6.23/100 000 person-years (95% CI 6.03 to 6.44). In cases with
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supporting evidence, the incidence was 4.58/100 000 person-
years (95% CI 4.40 to 4.76). The trends in age, gender, region,
year and ethnicity were similar between deﬁnitions (see online
supplementary table S2).
Prevalence
During the study period, there were 7732 eligible prevalent
cases with SLE of which 6634 were female (86%).
Temporal trend
There was a linear 3.1% increasing annual trend in prevalence
from 64.63/100 000 in 1999 (95% CI 61.74 to 67.62) to
97.04/100 000 in 2012 (95% CI 94.19 to 99.94) (p for
trend<0.001) (table 1). Adjusting for length of follow-up, in
addition to age and gender there remained an increasing linear
trend of 2.5% (95% CI 2.3 to 2.8, p<0.001).
Age and gender
In every year, females had a signiﬁcantly higher prevalence of
SLE than males. There was an increasing trend in both genders,
which was more marked in females such that the ratio between
genders increased from 5.07 (95% CI 4.48 to 5.73) in 1999 to
6.75 (95% CI 6.18 to 7.38) in 2012 (ﬁgure 3).
The overall peak age of prevalence was 60–69 years. The
peak age in prevalence for men (80–89 years) was later than
that of women (60–69 years) (ﬁgure 1B).
Region
In 1999, the North East had the lowest prevalence (45.88/
100 000 (95% CI (30.21 to 61.56)) and Northern Ireland the
highest (94.42/100 000 (95% CI 73.39 to 115.44)), whereas in
2012 the East Midlands had the lowest prevalence (65.16/
100 000 (95% CI 48.52 to 85.68)) and Northern Ireland
remained the highest (120.12/100 000 (95% CI 103.39 to
138.78)) (ﬁgure 2B).
Ethnicity
In all, 2 812 963 of the 4 547 778 denominator population in
2012 attended HES-linked practices (61.9%) and were eligible
for this analysis. Table 2 shows the variation in prevalence with
ethnicity on 1 July 2012. Similar to incidence, people of Black
Table 1 SLE incidence rate (IR) and prevalence by year, 1999–2012
Year
Number of
incident
cases Person-years
Crude IR, per
100 000 person-years
(95% CI)
Standardised IR*, per
100 000 person-years
(95% CI)
Number of
prevalent
cases
Crude point prevalence,
per 100 000 (95% CI)
Standardised point
prevalence*, per 100 000
person-years (95% CI)
1999 138 2 708 850 5.09 (4.31 to 6.02) 5.10 (4.25 to 5.96) 1875 64.63 (61.74 to 67.62) 64.99 (62.04 to 67.93)
2000 191 3 221 486 5.93 (5.15 to 6.83) 5.87 (5.03 to 6.71) 2312 66.67 (63.98 to 69.44) 66.60 (63.87 to 69.33)
2001 189 3 558 271 5.31 (4.61 to 6.13) 5.30 (4.54 to 6.06) 2674 69.78 (67.16 to 72.47) 69.97 (67.30 to 72.63)
2002 226 3 850 272 5.87 (5.15 to 6.69) 5.82 (5.06 to 6.59) 3062 73.21 (70.64 to 75.85) 73.77 (71.15 to 76.38)
2003 209 4 010 316 5.21 (4.55 to 5.97) 5.19 (4.49 to 5.90) 3319 76.24 (73.67 to 78.88) 76.99 (74.36 to 79.61)
2004 182 4 166 948 4.34 (3.75 to 5.02) 4.34 (3.71 to 4.98) 3528 78.00 (75.45 to 80.62) 78.04 (75.46 to 80.62)
2005 236 4 285 893 5.53 (4.87 to 6.28) 5.54 (4.84 to 6.25) 3775 81.23 (78.66 to 83.86) 81.26 (78.66 to 83.86)
2006 179 4 326 228 4.14 (3.57 to 4.79) 4.13 (3.53 to 4.74) 3902 83.65 (81.05 to 86.32) 84.39 (81.74 to 87.05)
2007 213 4 365 260 4.88 (4.27 to 5.58) 4.85 (4.20 to 5.51) 4076 86.31 (83.68 to 89.00) 87.18 (84.49 to 89.86)
2008 213 4 369 525 4.87 (4.26 to 5.58) 4.87 (4.22 to 5.53) 4190 88.62 (85.96 to 91.35) 88.61 (85.93 to 91.29)
2009 195 4 385 184 4.42 (3.84 to 5.09) 4.42 (3.80 to 5.05) 4316 91.16 (88.46 to 93.92) 91.17 (88.46 to 93.89)
2010 173 4 324 739 4.02 (3.47 to 4.67) 4.03 (3.43 to 4.63) 4382 93.45 (90.70 to 96.26) 94.61 (91.80 to 97.43)
2011 209 4 239 545 4.93 (4.30 to 5.65) 4.92 (4.26 to 5.59) 4429 95.81 (93.01 to 98.67) 96.67 (93.81 to 99.53)
2012 187 4 026 564 4.64 (4.02 to 5.36) 4.64 (3.98 to 5.31) 4413 97.04 (94.19 to 99.94) 97.04 (94.18 to 99.90)
*By age and gender to the population of 2012.
SLE, systemic lupus erythematosus.
Figure 1 Line chart of age and gender-speciﬁc (A) incidence rate 1999–2012 and (B) point prevalence in 2012 for systemic lupus erythematosus.
Clinical and epidemiological research
138 Rees F, et al. Ann Rheum Dis 2016;75:136–141. doi:10.1136/annrheumdis-2014-206334
group.bmj.com on January 9, 2016 - Published by http://ard.bmj.com/Downloaded from 
Caribbean ethnicity had the highest prevalence (517.51 per
100 000 people, 95% CI 398.54 to 660.84).
Alternative deﬁnitions
The prevalence of SLE in 2012 with the fully comprehensive def-
inition was 125.51/100 000 (95% CI 122.26 to 128.76) and in
cases with supporting evidence was 88.09/100 000 (95% CI
85.38 to 90.86). The trends for year, age, gender, region and eth-
nicity were similar to that of the ﬁrst deﬁnition, with variation in
the regional differences (see online supplementary table S2).
DISCUSSION
For people with our primary deﬁnition of SLE, the incidence for
1999–2012 was 4.91 per 100 000 person-years (95% CI 4.73 to
5.09) and the prevalence in 2012 was 97.04 per 100 000 people
(95% CI 94.19 to 99.94). Our ﬁndings suggest that although the
prevalence is increasing, the incidence is decreasing. We conﬁrm
the female predominance, which is approximately six times that
of males. The peak age of incidence is 50–59 years. There is
regional variation in incidence and prevalence of SLE with the
highest incidence in the East of England and the highest preva-
lence in Northern Ireland. Black Caribbean is the ethnic group
with the highest incidence and prevalence. Similar trends were
found with all 3 deﬁnitions of SLE.
Our estimates of incidence and prevalence of SLE are higher
than those of previous UK studies.1–5 7–9 Although this could be
due to increases with time, our incidence decreased with time.
A more likely explanation is that our primary deﬁnition
included subtypes of SLE such as lupus nephritis and cerebral
lupus which may have been excluded from previous studies. For
example, Hopkinson et al1 invited cases for assessment, veriﬁed
the diagnosis in person and required cases to meet the ACR cri-
teria for SLE. This would have excluded minor cases, those with
single organ disease and those unwilling to attend for
assessment, which would have been included in our study. Our
incidence estimate was similar to Somers et al8 who used the
CPRD during the period 1990–1999. However, they included
cases with subacute cutaneous lupus. In contrast, Nightingale
et al7 had a signiﬁcantly lower incidence of SLE despite includ-
ing cases with discoid lupus as they required 3 years of registra-
tion before diagnosis plus supporting evidence within the
medical record. Their estimate remained lower than our third
deﬁnition which required supporting evidence (4.30/100 000
person-years (95% CI 4.13 to 4.48)). The incidence found with
our fully comprehensive deﬁnition of lupus (6.23/100 000
person-years (95% CI 6.03 to 6.44)) is much higher than previ-
ous UK studies of SLE and is the ﬁrst study in the UK to include
all cutaneous and systemic subtypes enabling an estimate of the
full burden of lupus in the community. Interestingly, this esti-
mate is still lower than some international studies of SLE inci-
dence, for example from Taiwan,18 Argentina19 and Brazil,20
demonstrating the variation between countries due to racial,
genetic and environmental factors and also differences due to
case deﬁnition and study methodology. With all 3 deﬁnitions,
the estimated prevalence for SLE was above the European
Union threshold for a ’rare disease’.21
The observed 50% increase in prevalence with time may be
true as it occurred with all 3 deﬁnitions, for example, due to
improved survival in people with SLE or due to ageing of the
entire UK population. However, the latter is less likely as our
estimates were age standardised. It may be due to more accurate
recording within electronic records as paper notes have been
replaced. Previous database studies have observed that the preva-
lence of chronic diseases appears to increase with time due to
length of data contribution, including one SLE study with a
61% increase in prevalence from 1992 to 1998.9 22 However,
after adjusting for length of data contribution, our prevalence
still increased with time. The decrease in incidence may be true
Figure 2 Choropleth map of age and gender standardised systemic lupus erythematosus (A) incidence rate (IR) 1999–2012 and (B) point
prevalence in 2012.
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or due to the possibility that prevalent cases were coded as inci-
dent cases in the early years of the study period. However,
increasing the minimum registration period to 3 years there
remained a small but signiﬁcant negative trend with time, sug-
gesting this was a true decrease.
When examining differences with age and gender, our study
conﬁrmed the known female predominance for people diag-
nosed with SLE, which was observed with every deﬁnition of
SLE. The mean age of diagnosis of 49 years and peak age of
incidence of 50–59 years is later than that which is convention-
ally taught, but is consistent with previous UK and some inter-
national studies.1 7 8 23 24 Males had a statistically signiﬁcant
later peak age of diagnosis compared with females in accord
with ﬁndings from previous studies worldwide.8 24–27
Although there was no clear trend with latitude, there were
statistically signiﬁcant regional differences in both SLE incidence
and prevalence. Regional variation has been noted previously by
Somers et al8 who also found the West Midlands to have the
lowest incidence and but in contrast to our study found
Northern Ireland to have the highest incidence. Reasons for this
regional variation are unclear but may be due to a combination
of local environmental or genetic factors, variation in ethnic
mix or socio-economic factors, differences in coding,
consultation, diagnosis or referral rates or differences in health-
seeking behaviour between the populations.
Ethnicity is recognised to be an important factor in the devel-
opment of SLE. This is the ﬁrst study to report ethnic variation
in SLE incidence and prevalence using the CPRD. We found
that people of Black Caribbean origin had the highest incidence
and prevalence of SLE. Combining ethnic groups, people of
Asian descent had the second highest incidence and prevalence
after Black people, and White people had the lowest incidence
and prevalence of SLE. This supports ﬁndings from previous
UK studies.2 28
The main limitations of our study are those inherent in the use
of a large database such as the CPRD. The date of diagnosis and
accuracy of diagnosis could not be veriﬁed which may have led to
missing data and misclassiﬁcation bias. Unfortunately, we were
unable to externally validate our cases. However, GPs would be
unlikely to Read code a diagnosis of SLE without conﬁrmation
from secondary care (personal communication, GD) and previ-
ous studies of other chronic autoimmune diseases have shown
good accuracy in recording on the CPRD with positive predictive
values >90%.16 17 Ideally, every case should be assessed in
person, but this is impractical due to the conﬁdentiality of the
database. Another limitation was that ethnicity data were only
available for individuals attending English HES-linked practices
and within these practices 50% of individuals had missing ethni-
city data. This may have caused an overestimation of the ethnic-
speciﬁc incidence and prevalence as people with ethnicity
recorded are those admitted to hospital and hence more likely to
have a chronic condition such as SLE. However, this should not
affect the rate ratios between ethnic groups and therefore the
trends remain valid. In addition, to maintain the sample size for
the analysis of region, age and gender, ethnicity could not be
adjusted for. This would be an interesting future study.
In summary, the incidence of SLE in the UK is decreasing and
the prevalence increasing. This increase in prevalence suggests
that SLE is no longer a ’rare’ disease, which has implications for
healthcare planning. These data conﬁrm the known predilection
for SLE in women. The peak age of diagnosis is in middle age,
contrary to the generally held belief that lupus mainly targets
young people. There is UK-wide variation. Black Caribbean is
the ethnic group with the highest incidence and prevalence.
Future research on geographic variation and ethnicity is
warranted.
Table 2 SLE incidence rate (IR) 1999–2012 and point prevalence in 2012 by ethnic group in HES-linked practices
Ethnicity Incident cases Person-years
Crude IR, per 100 000
person-years (95% CI) Prevalent cases Denominator
Point prevalence per
100 000 (95% CI)
Bangladeshi 0 32 671 0.00 4 4983 80.27 (21.87 to 205.53)
Black African 15 108 883 13.78 (8.31 to 22.85) 35 19 465 179.81 (125.24 to 250.07)
Black Caribbean 34 108 073 31.46 (22.48 to 44.03) 64 12 367 517.51 (398.54 to 660.84)
Black other 12 53 923 22.25 (12.64 to 39.19) 29 8393 345.53 (231.40 to 496.23)
Chinese 4 42 785 9.35 (3.51 to 24.91) 10 5308 188.39 (90.34 to 346.46)
Indian 19 191 858 9.90 (6.32 to 15.53) 45 23 305 193.09 (140.84 to 258.37)
Mixed 12 102 833 11.67 (6.63 to 20.55) 24 17 372 138.15 (88.52 to 205.56)
Other Asian 14 80 227 17.45 (10.34 to 29.46) 23 12 864 178.79 (113.34 to 268.28)
Other 13 237 185 5.48 (3.18 to 9.44) 40 27 921 143.26 (102.35 to 195.08)
Pakistani 11 110 598 9.95 (5.51 to 17.96) 24 16 808 142.79 (91.49 to 212.46)
Unknown 229 4 858 127 4.71 (4.14 to 5.37) 346 387 193 89.36 (80.19 to 99.29)
White 1098 16 303 929 6.73 (6.35 to 7.14) 1700 1 263 646 134.53 (128.21 to 141.08)
Unclassified 182 12 141 118 1.50 (1.30 to 1.73) 353 1 013 338 34.84 (31.30 to 38.67)
HES, Hospital Episode Statistics; SLE, systemic lupus erythematosus.
Figure 3 Annual systemic lupus erythematosus prevalence by gender.
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